Invesco Pharmaceuticals ETF
PJP
89 hedge funds and large institutions have $63.6M invested in Invesco Pharmaceuticals ETF in 2024 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 29 reducing their positions, and 11 closing their positions.
0.25% more ownership
Funds ownership: 22.88% → 23.13% (+0.25%)
3% less capital invested
Capital invested by funds: $65.7M → $63.6M (-$2.05M)
4% less funds holding
Funds holding: 93 → 89 (-4)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
34% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.08M |
| 2 |
DBIA
Dumont & Blake Investment Advisors
Princeton,
New Jersey
|
+$1.58M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$886K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$696K |
| 5 |
P
&Partners
Nashville,
Tennessee
|
+$297K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$2.31M |
| 2 |
FGA
Fortis Group Advisors
Westwood,
New Jersey
|
-$2.06M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$748K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$677K |
| 5 |
Morgan Stanley
New York
|
-$670K |
PJP Hedge Fund Activity: Q2 2024 in Review
89 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q2 2024, worth a combined $63.6M — down 3.1% from $65.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PJP and 9 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 19 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $2.08M. The largest seller was LPL Financial, cutting an estimated $2.31M.
- 89 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q2 2024, down from 93 in Q1 2024.
- Funds reported $63.6M of Invesco Pharmaceuticals ETF stock for Q2 2024, down 3.1% quarter-over-quarter.
- 9 funds opened new Invesco Pharmaceuticals ETF positions in Q2 2024 and 11 closed out, a net change of -2 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q2 2024 was Goldman Sachs, an estimated $2.08M added.
- The largest Invesco Pharmaceuticals ETF seller in Q2 2024 was LPL Financial, an estimated $2.31M sold.
Based on aggregated 13F filings for Q2 2024.